A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
Condition: Attention Deficit Disorder With Hyperactivity Interventions: Drug: MPH (Concerta); Drug: MPH (Ritalin); Drug: Atomoxetine (ATO); Drug: Guanfacine (GFC) Sponsor: Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials